Stocks › RLAY

Relay Therapeutics, Inc.

RLAY·Nasdaq·United States United States·USD
$16.12
+0.21 (+1.32%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RLAY
Relay Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RLAYS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of RLAY by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY RLAYRelay Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Aug 13, 2023 Jul 12, 2023 Filing ↗

Whale Activity

Position changes in RLAY reported for 2026-09-30 by 290 institutional filers
Increased: 95New: 30Held: 45Decreased: 80Closed: 30No prior filing: 10
  • Increased95
  • New30
  • Held45
  • Decreased80
  • Closed30
  • No prior filing10
FilerSharesValueChange
FMR LLC24.2M$437.5Mincreased
SB INVESTMENT ADVISERS (UK) LTD21.9M$395.4Mdecreased
T. Rowe Price Investment Management, Inc.17.9M$322.5Mincreased
BlackRock, Inc.16.7M$301.4Mincreased
Casdin Capital, LLC16.0M$289.4Mheld
PERCEPTIVE ADVISORS LLC12.7M$229.8Mdecreased
Commodore Capital LP12.0M$216.6Mheld
STATE STREET CORP9.2M$165.2Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC9.0M$162.7Mincreased
Nextech Invest Ltd.6.8M$122.3Mheld
PRICE T ROWE ASSOCIATES INC /MD/6.6M$119.7Mdecreased
Bellevue Group AG6.2M$111.7Mheld

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by RLAY insiders, by quarter · Form 4
-10.0M-5.0M05.0M10.0M2025 Q1: -917.1K2025 Q12025 Q2: -138.9K2025 Q22025 Q3: -149.2K2025 Q32025 Q4: -155.2K2025 Q42026 Q1: -111.0K2026 Q12026 Q2: -371.1K2026 Q22026 Q3: -6.2M2026 Q32026 Q4: -161.6K2026 Q4

Recent Insider Transactions

395 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Patel SanjivPresident and CEO · Director Sale −48.2K $16.13 $777K Nov 19, 2026 Form 4 ↗
Bergstrom Donald APresident, R&D Sale −10.3K $16.51 $170K Nov 18, 2026 Form 4 ↗
Catinazzo ThomasChief Financial Officer Sale −32.7K $16.51 $540K Nov 18, 2026 Form 4 ↗
Rahmer PeterSee remarks Sale −753 $18.62 $14K Oct 28, 2026 Form 4 ↗
Bergstrom Donald APresident, R&D Sale −2,252 $18.62 $42K Oct 28, 2026 Form 4 ↗
Catinazzo ThomasChief Financial Officer Sale −1,469 $18.62 $27K Oct 28, 2026 Form 4 ↗
Patel SanjivPresident and CEO · Director Sale −48.2K $18.10 $872K Oct 7, 2026 Form 4 ↗
Catinazzo ThomasChief Financial Officer Sale −206 $19.26 $4K Oct 6, 2026 Form 4 ↗
Catinazzo ThomasChief Financial Officer Sale −17.5K $18.58 $325K Oct 6, 2026 Form 4 ↗
Bergstrom Donald APresident, R&D Sale −8,530 $18.97 $162K Sep 8, 2026 Form 4 ↗
Catinazzo ThomasChief Financial Officer Sale −17.7K $18.94 $336K Sep 8, 2026 Form 4 ↗
Patel SanjivPresident and CEO · Director Sale −48.2K $18.94 $913K Sep 8, 2026 Form 4 ↗
Rahmer PeterSee remarks Sale −4,508 $20.03 $90K Aug 26, 2026 Form 4 ↗
SB INVESTMENT ADVISERS (UK) LTD10% owner Sale −6.0M $19.40 $116.4M Aug 25, 2026 Form 4 ↗
Patel SanjivPresident and CEO · Director Sale −48.2K $20.33 $980K Aug 17, 2026 Form 4 ↗
Catinazzo ThomasChief Financial Officer Sale −17.7K $19.74 $350K Aug 14, 2026 Form 4 ↗
Catinazzo ThomasChief Financial Officer Sale −1,459 $18.61 $27K Jul 28, 2026 Form 4 ↗
Rahmer PeterSee remarks Sale −748 $18.61 $14K Jul 28, 2026 Form 4 ↗
Bergstrom Donald APresident, R&D Sale −2,237 $18.61 $42K Jul 28, 2026 Form 4 ↗
Patel SanjivPresident and CEO · Director Sale −48.2K $19.58 $944K Jul 7, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding RLAY · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
6.8M$127.2M0.01%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
6.3M$118.0M1.10%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
4.2M$77.9M0.09%Jun 30, 2026
Select Health Care Portfolio
Fidelity Select Portfolios
2.1M$38.2M0.57%Aug 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.9M$36.4M0.04%Jun 30, 2026
Fidelity Small Cap Growth Fund
Fidelity Securities Fund
1.9M$36.1M0.41%Jul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund
Fidelity Rutland Square Trust II
1.9M$35.7M0.01%Aug 31, 2026
Fidelity Advisor Biotechnology Fund
Fidelity Advisor Series VII
1.9M$34.8M1.58%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1.8M$34.4M0.29%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.8M$33.3M0.10%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list RLAY's shares (CUSIP 75943R102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • T. Rowe Price Investment Management, Inc.SCHEDULE 13G · passive (13G) · 17.9M shares8.2%
    Nov 16, 2026 · ↗
  • SVF Pauling (Cayman) LtdSCHEDULE 13G/A · passive (13G) · 21.9M shares9.9%
    Nov 16, 2026 · ↗
  • SoftBank Vision Fund (AIV M2) L.P.SCHEDULE 13G/A · passive (13G) · 21.9M shares9.9%
    Nov 16, 2026 · ↗
  • SB Investment Advisers (UK) LimitedSCHEDULE 13G/A · passive (13G) · 21.9M shares9.9%
    Nov 16, 2026 · ↗
  • Michael KramarzSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
    Aug 14, 2026 · ↗
  • Robert Egen AtkinsonSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
    Aug 14, 2026 · ↗
  • Commodore Capital Master LPSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
    Aug 14, 2026 · ↗
  • Commodore Capital LPSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
    Aug 14, 2026 · ↗
  • Perceptive Life Sciences Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 14.1M shares6.4%
    Aug 10, 2026 · ↗
  • Joseph EdelmanSCHEDULE 13G/A · passive (13G) · 14.1M shares6.4%
    Aug 10, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Relay Therapeutics, Inc. as client

No lobbying filings found naming Relay Therapeutics, Inc. as the client.

Government Contracts

Federal awards to Relay Therapeutics, Inc. · USAspending

No federal contract awards found for Relay Therapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Relay Therapeutics, Inc.

No USPTO patent applications found for Relay Therapeutics, Inc..

Annual Financials

From RLAY's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$15.4M$10.0M$25.5M$1.4M$3.0M
Operating income-$302.7M-$372.5M-$373.0M-$299.3M-$364.7M
Net income-$276.5M-$337.7M-$342.0M-$290.5M-$363.9M
Diluted EPS-$1.61-$2.36-$2.79-$2.59-$3.82
Operating cash flow-$235.5M-$249.1M-$300.3M-$229.5M-$74.4M
Cash and equivalents$84.0M$124.3M$143.7M$151.8M$280.1M
Total assets$621.3M$871.3M$844.0M$1.10B$1.01B
Total liabilities$54.3M$93.5M$92.0M$149.6M$110.6M
Shareholders' equity$567.1M$777.8M$752.0M$950.2M$897.8M

As Relay Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in RLAY's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.02, 9.01Material agreement · Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteJun 9, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 9.01Material agreementMay 21, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsMay 19, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
    EDGAR ↗

About Relay Therapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE